0001104659-22-011519.txt : 20220203
0001104659-22-011519.hdr.sgml : 20220203
20220203195615
ACCESSION NUMBER: 0001104659-22-011519
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220131
FILED AS OF DATE: 20220203
DATE AS OF CHANGE: 20220203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harris Matthew Scott
CENTRAL INDEX KEY: 0001787762
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32587
FILM NUMBER: 22590430
MAIL ADDRESS:
STREET 1: C/O ALTIMMUNE, INC.
STREET 2: 910 CLOPPER ROAD, SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Altimmune, Inc.
CENTRAL INDEX KEY: 0001326190
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202726770
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 910 CLOPPER ROAD
STREET 2: SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 2406541450
MAIL ADDRESS:
STREET 1: 910 CLOPPER ROAD
STREET 2: SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
FORMER COMPANY:
FORMER CONFORMED NAME: PHARMATHENE, INC
DATE OF NAME CHANGE: 20071016
FORMER COMPANY:
FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP
DATE OF NAME CHANGE: 20050505
4
1
tm225504-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-01-31
0
0001326190
Altimmune, Inc.
ALT
0001787762
Harris Matthew Scott
C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,
SUITE 201S
GAITHERSBURG,
MD
20878
0
1
0
0
Chief Medical Officer
Common Stock, par value $0.0001
2022-01-31
4
A
0
1800
6.86
A
7562
D
Common Stock, par value $0.0001
2022-02-01
4
M
0
6166
0
A
13728
D
Common Stock, par value $0.0001
2022-02-01
4
F
0
2183
7.98
D
11545
D
Restricted Stock Units
2022-02-01
4
M
0
6166
0.00
D
Common Stock, par value $0.0001
6166
18498
D
Stock Options (option to buy)
7.53
2022-02-02
4
A
0
91600
0.00
A
2032-02-02
Common Stock, par value $0.0001
91600
91600
D
Restricted Stock Units
2022-02-02
4
A
0
31100
0.00
A
Common Stock, par value $0.0001
31100
31100
D
These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2021 through January 31, 2022.
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2022.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date.
The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
/s/ Kent Tapper, as Attorney-in-Fact
2022-02-03